United States Pharmaceuticals

Bristol-Myers Squibb Co (BMY)

Track

The most recent insider trading activity occurred on April 1, 2026, with proposed and planned sales by EVP, Chief Financial Officer David V. Elkins. Prior to this, transactions included planned sales in September 2025 and a sell transaction in August 2025. There were also several buy transactions by other executives in late 2024 and early 2025.
Ticker: BMY Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Bristol-Myers Squibb Co. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Elkins David V
EVP, Chief Financial Officer
3 sales — total 3,700,661 USD
Planned sale 1 Apr 2026
Value US$2,317,810.33 | Price 107.65 | Shares 56,268
Planned sale 1 Apr 2026
Value US$4,114,765.62 | Price 172.15 | Shares 73,125
Proposed sale 1 Apr 2026
Value US$1,850,644.69 | Price 61.69 | Shares 30,000
Planned sale 2 Sep 2025
Value US$878,457.40 | Price 121.83 | Shares 92,529
Proposed sale 2 Sep 2025
Value US$2,027,270.74 | Price 190.80 | Shares 28,900
Sale 2 Aug 2025
Value US$16,718.94 | Price 44.23 | Shares 378
Sale 9 May 2025
Value US$3,701.83 | Price 38.01 | Shares 97
Buy 25 Apr 2025
Value US$202,215.00 | Price 47.58 | Shares 4,250
Buy 20 Feb 2025
Value US$110,096.00 | Price 55.05 | Shares 2,000
Buy 14 Feb 2025
Value US$99,999.97 | Price 54.84 | Shares 1,823
Sale 4 Nov 2024
Value US$38,930.50 | Price 55.62 | Shares 700
Proposed sale 4 Nov 2024
Value US$38,930.50 | Price 55.62 | Shares 700
Buy 1 Nov 2024
Value US$100,055.25 | Price 54.68 | Shares 1,830
Buy 5 Dec 2023
Value US$99,560.00 | Price 49.78 | Shares 2,000
Buy 28 Nov 2023
Value US$150,049.06 | Price 48.86 | Shares 3,071
Buy 20 Nov 2023
Value US$423,385.00 | Price 49.81 | Shares 8,500
Sale 24 Aug 2023
Value US$1,101,642.50 | Price 61.25 | Shares 17,986
Proposed sale 24 Aug 2023
Value US$1,101,652.97 | Price 61.25 | Shares 17,986
Sale 3 Aug 2023
Value US$44,754.48 | Price 61.14 | Shares 732
Proposed sale 3 Aug 2023
Value US$44,756.44 | Price 61.14 | Shares 732
Sale 3 May 2023
Value US$3,378,818.10 | Price 67.06 | Shares 50,385
Proposed sale 3 May 2023
Value US$3,378,940.88 | Price 67.06 | Shares 50,385
Sale 6 Feb 2023
Value US$835,258.27 | Price 74.69 | Shares 11,183
Sale 6 Feb 2023
Value US$17,916,000.00 | Price 74.65 | Shares 240,000
Sale 9 Nov 2022
Value US$1,307,312.50 | Price 80.45 | Shares 16,250
Sale 7 Nov 2022
Value US$3,621,380.80 | Price 78.88 | Shares 45,910
Planned sale 20 Sep 2022
Value US$1,742,750.00 | Price 69.71 | Shares 25,000
Sale 15 Sep 2022
Value US$3,592,000.00 | Price 71.84 | Shares 50,000
Sale 14 Sep 2022
Value US$1,768,750.00 | Price 70.75 | Shares 25,000
Sale 13 Sep 2022
Value US$7,410,666.79 | Price 71.29 | Shares 103,951
Sale 13 Sep 2022
Value US$2,140,500.00 | Price 71.35 | Shares 30,000
Sale 13 Jun 2022
Value US$2,221,200.00 | Price 74.04 | Shares 30,000
Sale 6 Jun 2022
Value US$4,867,850.00 | Price 74.89 | Shares 65,000
Planned sale 21 Mar 2022
Value US$1,788,000.00 | Price 71.52 | Shares 25,000
Sale 16 Mar 2022
Value US$2,992,674.44 | Price 69.23 | Shares 43,228
Sale 16 Mar 2022
Value US$2,170,298.37 | Price 69.27 | Shares 31,331
Sale 14 Mar 2022
Value US$455,095.52 | Price 69.20 | Shares 6,577
Sale 14 Mar 2022
Value US$2,043,525.80 | Price 69.20 | Shares 29,532
Sale 24 Feb 2022
Value US$2,010,000.00 | Price 67.00 | Shares 30,000
Sale 16 Dec 2021
Value US$812,069.00 | Price 61.99 | Shares 13,100
Sale 16 Dec 2021
Value US$384,183.03 | Price 61.99 | Shares 6,198
Sale 24 Nov 2021
Value US$987,732.76 | Price 56.92 | Shares 17,353
Sale 23 Nov 2021
Value US$886,072.46 | Price 57.47 | Shares 15,418
Sale 22 Nov 2021
Value US$1,049,812.71 | Price 57.17 | Shares 18,363
Sale 30 Jul 2021
Value US$9,575,656.24 | Price 68.08 | Shares 140,653
Sale 30 Jul 2021
Value US$1,206,497.40 | Price 68.01 | Shares 17,740
Sale 10 May 2021
Value US$978,750.00 | Price 65.25 | Shares 15,000
Sale 5 May 2021
Value US$1,963,802.34 | Price 64.29 | Shares 30,546
Sale 5 May 2021
Value US$200,270.99 | Price 64.21 | Shares 3,119
Planned sale 22 Mar 2021
Value US$1,555,000.00 | Price 62.20 | Shares 25,000
Sale 25 Nov 2020
Value US$190.50 | Price 63.50 | Shares 3
Sale 24 Nov 2020
Value US$57,051.00 | Price 63.39 | Shares 900
Sale 24 Nov 2020
Value US$1,255,000.00 | Price 62.75 | Shares 20,000
Sale 23 Nov 2020
Value US$823,244.14 | Price 61.34 | Shares 13,421
Sale 19 Nov 2020
Value US$2,882,305.72 | Price 61.31 | Shares 47,012
Sale 19 Nov 2020
Value US$647,963.75 | Price 61.25 | Shares 10,579
Sale 31 Aug 2020
Value US$2,497,968.00 | Price 62.70 | Shares 39,840
Sale 17 Aug 2020
Value US$340,928.00 | Price 64.00 | Shares 5,327
Sale 13 Aug 2020
Value US$8,943,400.80 | Price 63.24 | Shares 141,420
Buy 15 Jun 2020
Value US$499,983.00 | Price 54.50 | Shares 9,174
Sale 22 May 2020
Value US$195,232.00 | Price 61.01 | Shares 3,200
Sale 19 May 2020
Value US$1,567,000.00 | Price 62.68 | Shares 25,000
Sale 4 Mar 2020
Value US$964,263.05 | Price 61.01 | Shares 15,805
Sale 2 Mar 2020
Value US$5,108,221.72 | Price 60.59 | Shares 84,308
Sale 5 Dec 2019
Value US$102,329.40 | Price 58.81 | Shares 1,740
Buy 4 Dec 2019
Value US$5,183.20 | Price 58.90 | Shares 88
Sale 5 Nov 2019
Value US$849,900.00 | Price 56.66 | Shares 15,000
Sale 5 Nov 2019
Value US$1,414,000.00 | Price 56.56 | Shares 25,000
Buy 31 Jul 2019
Value US$491,920.00 | Price 44.72 | Shares 11,000
Sale 16 May 2019
Value US$145,771.40 | Price 47.56 | Shares 3,065
Buy 16 May 2019
Value US$236,440.00 | Price 47.29 | Shares 5,000
Buy 30 Apr 2018
Value US$249,948.00 | Price 52.40 | Shares 4,770
Buy 15 Dec 2017
Value US$249,187.20 | Price 62.30 | Shares 4,000
Sale 12 Dec 2017
Value US$335,172.00 | Price 63.24 | Shares 5,300
Sale 4 Dec 2017
Value US$9,922,601.34 | Price 63.37 | Shares 156,582
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-02 2026-04-01 PlS Planned sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
56,268 +39.0%
107.65
US$2,317,810 		56,268 +39.0% 107.65 US$2,317,810
2026-04-02 2026-04-01 PlS Planned sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
73,125 +13.1%
172.15
US$4,114,766 		73,125 +13.1% 172.15 US$4,114,766
2026-04-01 2026-04-01 PrS Proposed sale
1.2
Elkins David V

Officer

Officer
74,032
345.39
US$3,170,906 		74,032 345.39 US$3,170,906
2025-09-03 2025-09-02 PlS Planned sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
56,000 -25.1%
47.33
US$2,650,480 		56,000 -25.1% 47.33 US$2,650,480
2025-09-02 2025-09-02 PrS Proposed sale
1.2
Elkins David V

Officer

Officer
56,000
47.30
US$2,648,800 		56,000 47.30 US$2,648,800
2025-08-05 2025-08-02 S Sale
0.8
Short Bartie Wendy

EVP, Corporate Affairs

Officer
378 -6.9%
44.23
US$16,719 		378 -6.9% 44.23 US$16,719
2025-05-13 2025-05-09 S Sale
Hickey Benjamin

President, RayzeBio Org.

Officer
97 -100.0%
38.01
US$3,702 		97 -100.0% 38.01 US$3,702
2025-04-29 2025-04-25 B Purchase
2.9
Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

Officer
4,250 +5.4%
47.58
US$202,215 		4,250 +5.4% 47.58 US$202,215
2025-02-21 2025-02-20 B Purchase
2.0
BOERNER CHRISTOPHER S.

Chief Executive Officer

Executive Director
2,000 +1.9%
55.05
US$110,096 		2,000 +1.9% 55.05 US$110,096
2025-02-19 2025-02-14 B Purchase
2.9
Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

Officer
1,823 +2.9%
54.84
US$100,000 		1,823 +2.9% 54.84 US$100,000
2024-11-05 2024-11-04 S Sale
0.9
Holzer Phil M

SVP and Controller

Officer
700 -5.6%
55.62
US$38,930 		700 -5.6% 55.62 US$38,930
2024-11-04 2024-11-04 PrS Proposed sale
0.9
Holzer Phil M

Officer

Officer
700
55.62
US$38,930 		700 55.62 US$38,930
2024-11-05 2024-11-01 B Purchase
2.9
Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

Officer
1,830 +3.0%
54.68
US$100,055 		1,830 +3.0% 54.68 US$100,055
2023-12-07 2023-12-05 B Purchase
2.0
BOERNER CHRISTOPHER S.

Chief Executive Officer

Officer
2,000 +2.5%
49.78
US$99,560 		2,000 +2.5% 49.78 US$99,560
2023-11-30 2023-11-28 B Purchase
2.0
BOERNER CHRISTOPHER S.

Chief Executive Officer

Officer
3,071 +4.0%
48.86
US$150,049 		3,071 +4.0% 48.86 US$150,049
2023-11-21 2023-11-20 B Purchase
3.4
Samuels Theodore R. II
Non-Executive Director
8,500 +31.5%
49.81
US$423,385 		8,500 +31.5% 49.81 US$423,385
2023-08-28 2023-08-24 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
17,986 -39.2%
61.25
US$1,101,642 		17,986 -39.2% 61.25 US$1,101,642
2023-08-24 2023-08-24 PrS Proposed sale
3.2
Powell Ann

Officer

Officer
17,986
61.25
US$1,101,653 		17,986 61.25 US$1,101,653
2023-08-07 2023-08-03 S Sale
2.9
Plenge Robert M

EVP, Chief Research Officer

Officer
732 -10.0%
61.14
US$44,754 		732 -10.0% 61.14 US$44,754
2023-08-03 2023-08-03 PrS Proposed sale
2.9
Plenge Robert M

Officer

Officer
732
61.14
US$44,756 		732 61.14 US$44,756
2023-05-04 2023-05-03 S Sale
3.3
VESSEY RUPERT

EVP & President, Research

Officer
50,385 -51.3%
67.06
US$3,378,818 		50,385 -51.3% 67.06 US$3,378,818
2023-05-03 2023-05-03 PrS Proposed sale
3.3
VESSEY RUPERT

Officer

Officer
50,385
67.06
US$3,378,941 		50,385 67.06 US$3,378,941
2023-02-08 2023-02-06 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
11,183 -32.7%
74.69
US$835,258 		11,183 -32.7% 74.69 US$835,258
2023-02-08 2023-02-06 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
240,000 -50.4%
74.65
US$17,916,000 		240,000 -50.4% 74.65 US$17,916,000
2022-11-14 2022-11-09 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
16,250 -32.2%
80.45
US$1,307,312 		16,250 -32.2% 80.45 US$1,307,312
2022-11-09 2022-11-07 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
45,910 -44.6%
78.88
US$3,621,381 		45,910 -44.6% 78.88 US$3,621,381
2022-09-22 2022-09-20 PlS Planned sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
25,000 -5.0%
69.71
US$1,742,750 		25,000 -5.0% 69.71 US$1,742,750
2022-09-16 2022-09-15 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
50,000 -9.1%
71.84
US$3,592,000 		50,000 -9.1% 71.84 US$3,592,000
2022-09-15 2022-09-14 S Sale
3.2
Powell Ann

EVP, Chief Human Resources

Officer
25,000 -33.1%
70.75
US$1,768,750 		25,000 -33.1% 70.75 US$1,768,750
2022-09-15 2022-09-13 S Sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
103,951 -46.5%
71.29
US$7,410,667 		103,951 -46.5% 71.29 US$7,410,667
2022-09-15 2022-09-13 S Sale
1.2
Elkins David V

EVP, Chief Financial Officer

Officer
30,000 -23.0%
71.35
US$2,140,500 		30,000 -23.0% 71.35 US$2,140,500
2022-06-14 2022-06-13 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
30,000 -5.2%
74.04
US$2,221,200 		30,000 -5.2% 74.04 US$2,221,200
2022-06-07 2022-06-06 S Sale
2.8
LEUNG SANDRA

EVP, General Counsel

Officer
65,000 -17.4%
74.89
US$4,867,850 		65,000 -17.4% 74.89 US$4,867,850
2022-03-23 2022-03-21 PlS Planned sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
25,000 -4.1%
71.52
US$1,788,000 		25,000 -4.1% 71.52 US$1,788,000
2022-03-18 2022-03-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
43,228 -46.2%
69.23
US$2,992,674 		43,228 -46.2% 69.23 US$2,992,674
2022-03-18 2022-03-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
31,331 -40.4%
69.27
US$2,170,298 		31,331 -40.4% 69.27 US$2,170,298
2022-03-16 2022-03-14 S Sale
1.6
Santiago Karen Murphy

SVP & Controller

Officer
6,577 -28.3%
69.20
US$455,096 		6,577 -28.3% 69.20 US$455,096
2022-03-16 2022-03-14 S Sale
2.0
BOERNER CHRISTOPHER S.

EVP, Chief Commercial Officer

Officer
29,532 -41.3%
69.20
US$2,043,526 		29,532 -41.3% 69.20 US$2,043,526
2022-02-28 2022-02-24 S Sale
3.5
Caforio Giovanni

Board Chair and CEO

Executive Director
30,000 -6.2%
67.00
US$2,010,000 		30,000 -6.2% 67.00 US$2,010,000
2021-12-17 2021-12-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
13,100 -29.1%
61.99
US$812,069 		13,100 -29.1% 61.99 US$812,069
2021-12-17 2021-12-16 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
6,198 -12.1%
61.99
US$384,183 		6,198 -12.1% 61.99 US$384,183
2021-11-24 2021-11-24 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
17,353 -21.5%
56.92
US$987,733 		17,353 -21.5% 56.92 US$987,733
2021-11-24 2021-11-23 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
15,418 -16.0%
57.47
US$886,072 		15,418 -16.0% 57.47 US$886,072
2021-11-24 2021-11-22 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
18,363 -16.0%
57.17
US$1,049,813 		18,363 -16.0% 57.17 US$1,049,813
2021-08-03 2021-07-30 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
140,653 -75.0%
68.08
US$9,575,656 		140,653 -75.0% 68.08 US$9,575,656
2021-08-03 2021-07-30 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
17,740 -32.6%
68.01
US$1,206,497 		17,740 -32.6% 68.01 US$1,206,497
2021-05-11 2021-05-10 S Sale
2.4
Schmukler Louis S

EVP,Pres.,Glob.Prod. & Supply

Officer
15,000 -31.9%
65.25
US$978,750 		15,000 -31.9% 65.25 US$978,750
2021-05-07 2021-05-05 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
30,546 -40.4%
64.29
US$1,963,802 		30,546 -40.4% 64.29 US$1,963,802
2021-05-07 2021-05-05 S Sale
3.0
Dubow Adam

SVP,ChiefCompliance&EthicsOff.

Officer
3,119 -16.1%
64.21
US$200,271 		3,119 -16.1% 64.21 US$200,271
2021-03-24 2021-03-22 PlS Planned sale
3.5
Caforio Giovanni

Chairman and CEO

Executive Director
25,000 -4.5%
62.20
US$1,555,000 		25,000 -4.5% 62.20 US$1,555,000
2020-11-30 2020-11-25 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
3 -0.0%
63.50
US$190 		3 -0.0% 63.50 US$190
2020-11-25 2020-11-24 S Sale
3.0
Dubow Adam

SVP,ChiefCompliance&EthicsOff.

Officer
900 -5.6%
63.39
US$57,051 		900 -5.6% 63.39 US$57,051
2020-11-25 2020-11-24 S Sale
1.7
von Autenried Paul

EVP, Chief Information Officer

Officer
20,000 -13.6%
62.75
US$1,255,000 		20,000 -13.6% 62.75 US$1,255,000
2020-11-25 2020-11-23 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
13,421 -26.1%
61.34
US$823,244 		13,421 -26.1% 61.34 US$823,244
2020-11-23 2020-11-19 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
47,012 -47.8%
61.31
US$2,882,306 		47,012 -47.8% 61.31 US$2,882,306
2020-11-23 2020-11-19 S Sale
3.3
VESSEY RUPERT

EVP, Research & Early Dev.

Officer
10,579 -18.7%
61.25
US$647,964 		10,579 -18.7% 61.25 US$647,964
2020-09-02 2020-08-31 S Sale
3.5
Caforio Giovanni

Chairman and CEO

Executive Director
39,840 -8.2%
62.70
US$2,497,968 		39,840 -8.2% 62.70 US$2,497,968
2020-08-19 2020-08-17 S Sale
2.3
Eid Joseph

SVP,Head Glob. Medical Affairs

Officer
5,327 -67.8%
64.00
US$340,928 		5,327 -67.8% 64.00 US$340,928
2020-08-17 2020-08-13 S Sale
2.8
LEUNG SANDRA

EVP, General Counsel

Officer
141,420 -24.6%
63.24
US$8,943,401 		141,420 -24.6% 63.24 US$8,943,401
2020-06-16 2020-06-15 B Purchase
3.6
Paliwal Dinesh C
Non-Executive Director
9,174 +70.9%
54.50
US$499,983 		9,174 +70.9% 54.50 US$499,983
2020-05-26 2020-05-22 S Sale
3.0
Dubow Adam

SVP,ChiefCompliance&EthicsOff.

Officer
3,200 -16.6%
61.01
US$195,232 		3,200 -16.6% 61.01 US$195,232
2020-05-21 2020-05-19 S Sale
2.4
Schmukler Louis S

EVP,Pres.,Glob.Prod. & Supply

Officer
25,000 -48.3%
62.68
US$1,567,000 		25,000 -48.3% 62.68 US$1,567,000
2020-03-06 2020-03-04 S Sale
2.3
Elicker John E

EVP, Investor Relations

Officer
15,805 -21.2%
61.01
US$964,263 		15,805 -21.2% 61.01 US$964,263
2020-03-04 2020-03-02 S Sale
3.3
VESSEY RUPERT

Pres., Research & Early Dev.

Officer
84,308 -63.6%
60.59
US$5,108,222 		84,308 -63.6% 60.59 US$5,108,222
2019-12-09 2019-12-05 S Sale Dubow Adam

Chief Compliance & Ethics Offi

Officer
1,740 -9.9%
58.81
US$102,329 		1,740 -9.9% 58.81 US$102,329
2020-06-09 2019-12-04 B Purchase
3.0
BONNEY MICHAEL W
Non-Executive Director
88 +1.2%
58.90
US$5,183 		88 +1.2% 58.90 US$5,183
2019-11-06 2019-11-05 S Sale Elicker John E

SVP, Public Affairs & IR

Officer
15,000 -16.8%
56.66
US$849,900 		15,000 -16.8% 56.66 US$849,900
2019-11-06 2019-11-05 S Sale Schmukler Louis S

Pres., Global Mfg. & Supply

Officer
25,000 -43.9%
56.56
US$1,414,000 		25,000 -43.9% 56.56 US$1,414,000
2019-08-01 2019-07-31 B Purchase BERTOLINI ROBERT J Non-Executive Director
11,000 +2770.8%
44.72
US$491,920 		11,000 +2770.8% 44.72 US$491,920
2019-05-20 2019-05-16 S Sale
1.6
Santiago Karen Murphy

Controller
3,065 -50.0%
47.56
US$145,771 		3,065 -50.0% 47.56 US$145,771
2019-05-20 2019-05-16 B Purchase
3.4
Samuels Theodore R. II
5,000 +22.7%
47.29
US$236,440 		5,000 +22.7% 47.29 US$236,440
2018-05-02 2018-04-30 B Purchase Paliwal Dinesh C Non-Executive Director
4,770 +146.5%
52.40
US$249,948 		4,770 +146.5% 52.40 US$249,948
2017-12-18 2017-12-15 B Purchase Samuels Theodore R. II
4,000 +22.2%
62.30
US$249,187 		4,000 +22.2% 62.30 US$249,187
2017-12-13 2017-12-12 S Sale Lynch Thomas J. Jr.

EVP & Chief Scientific Officer
5,300 -36.4%
63.24
US$335,172 		5,300 -36.4% 63.24 US$335,172
2017-12-05 2017-12-04 S Sale LEUNG SANDRA

EVP, General Counsel
156,582 -26.8%
63.37
US$9,922,601 		156,582 -26.8% 63.37 US$9,922,601
Explore more

More insider trading research around Bristol-Myers Squibb Co

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America
Insider trades in S&P 500